NovaGray

About NovaGray

NovaGray is a pioneering startup in the healthcare sector, specifically focusing on radiotherapy for cancer patients. The company offers innovative tests that assess an individual's radiosensitivity, which is how sensitive a person is to radiation. This is crucial because nearly 10% of patients undergoing radiotherapy experience severe side effects. By identifying these hypersensitive patients before treatment begins, NovaGray aims to personalize and optimize each patient's care pathway.

The primary clients for NovaGray's services are healthcare providers, including oncologists and radiologists, who treat prostate and breast cancer patients. The company operates in the medical diagnostics market, with a particular focus on radiotherapy, a treatment method used for more than 50% of cancer patients.

NovaGray's business model revolves around selling its proprietary tests to healthcare institutions. These tests are based on a simple blood sample and have been validated through extensive clinical studies. The tests are recommended by the French Society of Radiation Oncology (SFRO), adding a layer of credibility and trust.

The company generates revenue by charging healthcare providers for each test conducted. This not only helps in personalizing treatment plans but also reassures patients and guides physicians in making informed decisions. By adapting patient follow-up after radiotherapy, NovaGray aims to improve overall treatment outcomes and reduce the risk of severe side effects.

In summary, NovaGray is revolutionizing cancer treatment by offering a personalized approach to radiotherapy, ensuring better patient outcomes and more efficient treatment plans.